Market Overview

Rexahn Pharma Expands Intellectual Property Related to Class of Anti-Cancer Isoquinolinamine Compounds

Related RNN
Rexahn Receives A Notice of Allowance From The U.S. Patent And Trademark Office For A Novel Targeted Cancer Drug Delivery Platform
Rexahn Presents Data from Preclinical Studies of RX-21102

Rexahn Pharmaceuticals, Inc. (NYSE: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has significantly expanded its intellectual property (IP) around isoquinolinamine, a class of potent anti-cancer compounds. Rexahn has been issued a continuation patent US 8,314,123 for US 8,034,829 to cover more new isoquinolinamine compounds and their pharmaceutical composition and method for producing an anti-tumor effect.

Posted-In: News FDA

 

Related Articles (RNN)

Around the Web, We're Loving...

Get Benzinga's Newsletters